{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:14:09Z","timestamp":1791951249207,"version":"4.3.4"},"reference-count":111,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T00:00:00Z","timestamp":1450915200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s00415-015-7963-5","type":"journal-article","created":{"date-parts":[[2015,12,24]],"date-time":"2015-12-24T09:08:53Z","timestamp":1450948133000},"page":"826-834","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":142,"title":["Myasthenia gravis: a clinical-immunological update"],"prefix":"10.1007","volume":"263","author":[{"given":"Sophie","family":"Binks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,12,24]]},"reference":[{"issue":"5","key":"7963_CR1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","volume":"8","author":"MN Meriggioli","year":"2009","unstructured":"Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8(5):475\u2013490","journal-title":"Lancet Neurol"},{"issue":"3","key":"7963_CR2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","volume":"7","author":"W Hoch","year":"2001","unstructured":"Hoch W, McConville J, Helms S et al (2001) Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 7(3):365\u2013368","journal-title":"Nat Med"},{"issue":"4","key":"7963_CR3","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","volume":"55","author":"J McConville","year":"2004","unstructured":"McConville J, Farrugia ME, Beeson D et al (2004) Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol 55(4):580\u2013584","journal-title":"Ann Neurol"},{"issue":"11","key":"7963_CR4","doi-asserted-by":"crossref","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","volume":"8","author":"I Koneczny","year":"2013","unstructured":"Koneczny I, Cossins J, Waters P et al (2013) MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One 8(11):e80695","journal-title":"PLoS One"},{"issue":"51","key":"7963_CR5","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R et al (2013) MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4. Proc Natl Acad Sci USA 110(51):20783\u201320788","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Pt 7","key":"7963_CR6","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","volume":"131","author":"MI Leite","year":"2008","unstructured":"Leite MI, Jacob S, Viegas S et al (2008) IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis. Brain 131(Pt 7):1940\u20131952","journal-title":"Brain"},{"issue":"8","key":"7963_CR7","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/archneurol.2012.437","volume":"69","author":"S Jacob","year":"2012","unstructured":"Jacob S, Viegas S, Leite MI et al (2012) Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 69(8):994\u20131001","journal-title":"Arch Neurol"},{"issue":"6","key":"7963_CR8","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jamaneurol.2015.0203","volume":"72","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Al-Hajjar M, Huda S et al (2015) Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis. JAMA Neurol 72(6):642\u2013649","journal-title":"JAMA Neurol"},{"key":"7963_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1749-6632.2012.06833.x","volume":"1275","author":"J Cossins","year":"2012","unstructured":"Cossins J, Belaya K, Zoltowska K et al (2012) The search for new antigenic targets in myasthenia gravis. Ann N Y Acad Sci 1275:123\u2013128","journal-title":"Ann N Y Acad Sci"},{"issue":"10","key":"7963_CR10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"18","author":"AS Carr","year":"2010","unstructured":"Carr AS, Cardwell CR, McCarron PO et al (2010) A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 18(10):46","journal-title":"BMC Neurol"},{"issue":"17","key":"7963_CR11","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1212\/WNL.0b013e318217e735","volume":"76","author":"Z Pakzad","year":"2011","unstructured":"Pakzad Z, Aziz T, Oger J (2011) Increasing incidence of myasthenia gravis among elderly in British Columbia, Canada. Neurology 76(17):1526\u20131528","journal-title":"Neurology"},{"issue":"6","key":"7963_CR12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","volume":"45","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Burns TM et al (2012) Recommendations for myasthenia gravis clinical trials. Muscle Nerve 45(6):909\u2013917","journal-title":"Muscle Nerve"},{"key":"7963_CR13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2012.06780.x","volume":"1275","author":"M Benatar","year":"2012","unstructured":"Benatar M, Sanders DB, Wolfe GI et al (2012) Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann N Y Acad Sci 1275:17\u201322","journal-title":"Ann N Y Acad Sci"},{"key":"7963_CR14","unstructured":"Clinical trials.gov. Efficacy of prednisone in the treatment of ocular myasthenia (EPITOME). ClinicalTrials.gov identifier NCT00995722 [on-line]. Web-page last updated 2015 Jan 6. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00995722?term=EPITOME&rank=1 . Accessed 13 Aug 2015"},{"issue":"12","key":"7963_CR15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","volume":"84","author":"B Keung","year":"2013","unstructured":"Keung B, Robeson KR, DiCapua DB et al (2013) Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients. J Neurol Neurosurg Psychiatry 84(12):1407\u20131409","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"7963_CR16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1196\/annals.1254.061","volume":"998","author":"GI Wolfe","year":"2003","unstructured":"Wolfe GI, Kaminski HJ, Jaretzki A et al (2003) Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann N Y Acad Sci 998:473\u2013480","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"7963_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","volume":"55","author":"GS Gronseth","year":"2000","unstructured":"Gronseth GS, Barohn RJ (2000) Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology 55(1):7\u201315","journal-title":"Neurology"},{"key":"7963_CR18","doi-asserted-by":"crossref","unstructured":"Cea G, Benatar M, Verdugo RJ et al (2013) Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 10:CD008111","DOI":"10.1002\/14651858.CD008111.pub2"},{"issue":"5","key":"7963_CR19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","volume":"85","author":"F Norwood","year":"2014","unstructured":"Norwood F, Dhanjal M, Hill M et al (2014) Myasthenia in pregnancy: best practice guidelines from a UK multispecialty working group. J Neurol Neurosurg Psychiatry 85(5):538\u2013543","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"7963_CR20","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","volume":"21","author":"E Kerty","year":"2014","unstructured":"Kerty E, Elsais A, Argov Z et al (2014) EFNS\/ENS Guidelines for the treatment of ocular myasthenia. Eur J Neurol 21(5):687\u2013693","journal-title":"Eur J Neurol"},{"issue":"3","key":"7963_CR21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","volume":"15","author":"J Sussman","year":"2015","unstructured":"Sussman J, Farrugia ME, Maddison P et al (2015) Myasthenia gravis: association of British Neurologists\u2019 management guidelines. Pract Neurol 15(3):199\u2013206","journal-title":"Pract Neurol"},{"issue":"11","key":"7963_CR22","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1007\/s00415-014-7520-7","volume":"261","author":"PMR Cruz","year":"2014","unstructured":"Cruz PMR, Palace J, Beeson D (2014) Inherited disorders of the neuromuscular junction: an update. J Neurol. 261(11):2234\u20132243","journal-title":"J Neurol."},{"issue":"1","key":"7963_CR23","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11910-013-0421-9","volume":"14","author":"SH Wong","year":"2014","unstructured":"Wong SH, Huda S, Vincent A et al (2014) Ocular myasthenia gravis: controversies and updates. Curr Neurol Neurosci Rep 14(1):421","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"5","key":"7963_CR24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1212\/WNL.47.5.1233","volume":"47","author":"LH Phillips","year":"1996","unstructured":"Phillips LH, Torner JC (1996) Epidemiologic evidence for a changing natural history of myasthenia gravis. Neurology 47(5):1233\u20131238","journal-title":"Neurology"},{"issue":"3","key":"7963_CR25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1136\/jnnp.71.3.352","volume":"71","author":"K Poulas","year":"2001","unstructured":"Poulas K, Tisbri E, Kokla A et al (2001) Epidemiology of seropositive myasthenia gravis in Greece. J Neurol Neurosurg Psychiatry 71(3):352\u2013356","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"7963_CR26","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","volume":"74","author":"A Vincent","year":"2003","unstructured":"Vincent A, Clover L, Buckley C et al (2003) Evidence of underdiagnosis of myasthenia gravis in older people. J Neurol Neurosurg Psychiatry 74(8):1105\u20131108","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"7963_CR27","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/jnnp.2008.152637","volume":"80","author":"N Matsui","year":"2009","unstructured":"Matsui N, Nakane S, Nakagawa Y et al (2009) Increasing incidence of elderly onset patients with myasthenia gravis in a local area of Japan. J Neurol Neurosurg Psychiatry 80(10):1168\u20131171","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1\u20132","key":"7963_CR28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jns.2011.03.004","volume":"305","author":"H Murai","year":"2011","unstructured":"Murai H, Yamashita N, Watanabe M et al (2011) Characteristics of myasthenia according to onset-age: Japanese nationwide survey. J Neurol Sci 305(1\u20132):97\u2013102","journal-title":"J Neurol Sci"},{"issue":"6","key":"7963_CR29","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/01.wnl.0000176067.32186.a3","volume":"65","author":"FE Somnier","year":"2005","unstructured":"Somnier FE (2005) Increasing incidence of late-onset anti-AChR antibody-seropositive myasthenia gravis. Neurology 65(6):928\u2013930","journal-title":"Neurology"},{"issue":"6","key":"7963_CR30","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/archdischild-2013-304788","volume":"99","author":"JR Parr","year":"2014","unstructured":"Parr JR, Andrew MJ, Finnis M et al (2014) How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child 99(6):539\u2013542","journal-title":"Arch Dis Child"},{"issue":"5","key":"7963_CR31","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/mus.23964","volume":"48","author":"N Alkhawajah","year":"2013","unstructured":"Alkhawajah N, Oger J (2013) Late-onset myasthenia gravis: a review when incidence in older adults keeps increasing. Muscle Nerve 48(5):705\u2013710","journal-title":"Muscle Nerve"},{"issue":"282","key":"7963_CR32","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2015.03.018","volume":"15","author":"RH Meel de","year":"2015","unstructured":"de Meel RH, Lipka AF, van Zwet EW et al (2015) Prognostic factors for exacerbations and emergency treatments in myasthenia gravis. J Neuroimmunol 15(282):123\u2013125","journal-title":"J Neuroimmunol"},{"issue":"11","key":"7963_CR33","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/j.1532-5415.2000.tb02635.x","volume":"48","author":"A Evoli","year":"2000","unstructured":"Evoli A, Batocchi AP, Minisci C et al (2000) Clinical characteristics and prognosis of myasthenia gravis in older people. J Am Geriatr Soc 48(11):1442\u20131448","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"7963_CR34","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1007\/s00415-012-6478-6","volume":"259","author":"SA \u017divkovi\u0107","year":"2012","unstructured":"\u017divkovi\u0107 SA, Clemens PR, Lacomis D (2012) Characteristics of late-onset myasthenia gravis. J Neurol 259(10):2167\u20132171","journal-title":"J Neurol"},{"issue":"3","key":"7963_CR35","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/brain\/103.3.579","volume":"103","author":"DA Compston","year":"1980","unstructured":"Compston DA, Vincent A, Newsom-Davis J et al (1980) Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103(3):579\u2013601","journal-title":"Brain"},{"issue":"2","key":"7963_CR36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ni1033","volume":"5","author":"PJ Linton","year":"2004","unstructured":"Linton PJ, Dorshkind K (2004) Age-related changes in lymphocyte development and function. Nat Immunol 5(2):133\u2013139","journal-title":"Nat Immunol"},{"issue":"4","key":"7963_CR37","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00415-015-7673-z","volume":"262","author":"A Uzawa","year":"2015","unstructured":"Uzawa A, Kawaguchi N, Kanai T et al (2015) Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis. J Neurol 262(4):1019\u20131023","journal-title":"J Neurol"},{"issue":"6","key":"7963_CR38","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0003-4975(99)00167-8","volume":"67","author":"M Tsuchida","year":"1999","unstructured":"Tsuchida M, Yamoto Y, Souma T et al (1999) Efficacy and safety of extended thymectomy for elderly patients with myasthenia gravis. Ann Thorac Surg 67(6):1563\u20131567","journal-title":"Ann Thorac Surg"},{"key":"7963_CR39","unstructured":"UK clinical research network study portfolio. A prospective study of late-onset myasthenia gravis. UKCRN 13582 [on-line]. http:\/\/public.ukcrn.org.uk\/search\/StudyDetail.aspx?StudyID=13582 . Accessed 13 Aug 2015"},{"issue":"9","key":"7963_CR40","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/(SICI)1097-4598(199909)22:9<1297::AID-MUS22>3.0.CO;2-C","volume":"22","author":"LH Phillips","year":"1999","unstructured":"Phillips LH, Juel VC (1999) Myasthenia gravis in the tenth decade. Muscle Nerve 22(9):1297\u20131298","journal-title":"Muscle Nerve"},{"issue":"18","key":"7963_CR41","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","volume":"72","author":"A Alshekhlee","year":"2009","unstructured":"Alshekhlee A, Miles JD, Katirji B et al (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72(18):1548\u20131554","journal-title":"Neurology"},{"issue":"3","key":"7963_CR42","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/mus.20935","volume":"37","author":"AR Punga","year":"2008","unstructured":"Punga AR, Sawada M, Stalberg EV (2008) Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 37(3):300\u2013307","journal-title":"Muscle Nerve"},{"issue":"12","key":"7963_CR43","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","volume":"60","author":"DB Sanders","year":"2003","unstructured":"Sanders DB, El-Salem K, Massey JM et al (2003) Clinical aspects of MuSK antibody positive seronegative MG. Neurology 60(12):1978\u20131980","journal-title":"Neurology"},{"issue":"Pt 10","key":"7963_CR44","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","volume":"126","author":"A Evoli","year":"2003","unstructured":"Evoli A, Tonali PA, Padua L et al (2003) Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 126(Pt 10):2304\u20132311","journal-title":"Brain"},{"issue":"1","key":"7963_CR45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Sanders DB, Evoli A (2011) Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 44(1):36\u201340","journal-title":"Muscle Nerve"},{"issue":"8","key":"7963_CR46","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","volume":"76","author":"D Lavrnic","year":"2005","unstructured":"Lavrnic D, Losen M, Vujic A et al (2005) The features of myasthenia gravis with autoantibodies to MuSK. J Neurol Neurosurg Psychiatry 76(8):1099\u20131102","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"7963_CR47","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"Pasnoor M, Wolfe GI, Nations S et al","year":"2010","unstructured":"Pasnoor M, Wolfe GI, Nations S et al (2010) Clinical findings in MuSK-antibody positive myasthenia gravis: a US experience. Muscle Nerve 41(3):370\u2013374","journal-title":"Muscle Nerve"},{"issue":"5","key":"7963_CR48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/01.wco.0000180660.57801.3f","volume":"18","author":"A Vincent","year":"2005","unstructured":"Vincent A, Leite MI (2005) Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 18(5):519\u2013525","journal-title":"Curr Opin Neurol"},{"issue":"11","key":"7963_CR49","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1212\/01.WNL.0000128042.28877.C3","volume":"62","author":"JH Yeh","year":"2004","unstructured":"Yeh JH, Chen WH, Chiu HC et al (2004) Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese. Neurology 62(11):2131\u20132132","journal-title":"Neurology"},{"issue":"8","key":"7963_CR50","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1468-1331.2009.02624.x","volume":"16","author":"P Tsiamalos","year":"2009","unstructured":"Tsiamalos P, Kordas G, Kokla A et al (2009) Epidemiological and immunological profile of muscle-specific kinase myasthenia gravis in Greece. Eur J Neurol 16(8):925\u2013930","journal-title":"Eur J Neurol"},{"issue":"4","key":"7963_CR51","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jnnp.2006.102517","volume":"78","author":"EH Niks","year":"2007","unstructured":"Niks EH, Kuks JB, Verschuuren JJ (2007) Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry 78(4):417\u2013418","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"7963_CR52","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","volume":"66","author":"EH Niks","year":"2006","unstructured":"Niks EH, Kuks JB, Roep BO et al (2006) Strong association of MuSK antibody\u2013positive myasthenia gravis and HLA-DR14-DQ5. Neurology 66(11):1772\u20131774","journal-title":"Neurology"},{"key":"7963_CR53","doi-asserted-by":"crossref","unstructured":"Bartoccioni E, Scuderi F, Augugliaro et al (2009) HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5. Neurology 72(2):195\u2013197","DOI":"10.1212\/01.wnl.0000339103.08830.86"},{"issue":"12","key":"7963_CR54","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.humimm.2013.08.271","volume":"74","author":"M Alahgholi-Hajibehzad","year":"2013","unstructured":"Alahgholi-Hajibehzad M, Yilmaz V, G\u00fclsen-Parman Y et al (2013) Association of HLA-DRB*1, -DRB*16 and -DQB1*05 with MuSK-myasthenia gravis in patients from Turkey. Hum Immunol 74(12):1633\u20131635","journal-title":"Hum Immunol"},{"issue":"9","key":"7963_CR55","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","volume":"78","author":"P Waters","year":"2012","unstructured":"Waters P, McKeon A, Leite MI et al (2012) Serologic diagnosis of NMO. A multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665\u2013671","journal-title":"Neurology"},{"key":"7963_CR56","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","volume":"270","author":"PM Rodr\u00edguez Cruz","year":"2015","unstructured":"Rodr\u00edguez Cruz PM, Huda S, L\u00f3pez-Ruiz P et al (2015) Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases. Exp Neurol 270:66\u201371","journal-title":"Exp Neurol"},{"issue":"1","key":"7963_CR57","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/ene.12270","volume":"21","author":"P Devic","year":"2014","unstructured":"Devic P, Petiot P, Simonet T et al (2014) Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol 21(1):130\u2013134","journal-title":"Eur J Neurol"},{"issue":"284","key":"7963_CR58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jneuroim.2015.04.015","volume":"15","author":"AI Tsonis","year":"2015","unstructured":"Tsonis AI, Zisimopoulou P, Lazaridis K et al (2015) MuSK autoantibodies in myasthenia gravis detected by cell based assay\u2014a multinational study. J Neuroimmunol 15(284):10\u201317","journal-title":"J Neuroimmunol"},{"issue":"1","key":"7963_CR59","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/joa.12034","volume":"224","author":"I Koneczny","year":"2014","unstructured":"Koneczny I, Cossins J, Vincent A (2014) The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 224(1):29\u201335","journal-title":"J Anat"},{"issue":"2","key":"7963_CR60","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","volume":"135","author":"N Kim","year":"2008","unstructured":"Kim N, Steigler AL, Cameron TO et al (2008) Lrp4 is a receptor for agrin and forms a complex with MuSK. Cell 135(2):334\u2013342","journal-title":"Cell"},{"issue":"2","key":"7963_CR61","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.neuron.2008.10.006","volume":"60","author":"B Zhang","year":"2008","unstructured":"Zhang B, Luo S, Wang Q et al (2008) LRP4 serves as a coreceptor of agrin. Neuron 60(2):285\u2013297","journal-title":"Neuron"},{"issue":"8","key":"7963_CR62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/ene.12758","volume":"22","author":"MG Huijbers","year":"2015","unstructured":"Huijbers MG, Querol LA, Niks EH et al (2015) The expanding field of IgG4-mediated neurological autoimmune disorders. Eur J Neurol 22(8):1151\u20131161","journal-title":"Eur J Neurol"},{"issue":"3","key":"7963_CR63","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","volume":"67","author":"E Bartoccioni","year":"2006","unstructured":"Bartoccioni E, Scuderi F, Minicuci GM et al (2006) Anti-MuSK antibodies: correlation with myasthenia gravis severity. Neurology 67(3):505\u2013507","journal-title":"Neurology"},{"issue":"1\u20132","key":"7963_CR64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","volume":"195","author":"EH Niks","year":"2008","unstructured":"Niks EH, van Leeuwen Y, Leite MI et al (2008) Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 195(1\u20132):151\u2013156","journal-title":"J Neuroimmunol"},{"issue":"Pt 4","key":"7963_CR65","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","volume":"135","author":"R Klooster","year":"2012","unstructured":"Klooster R, Plomp JJ, Huijbers MG et al (2012) Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 135(Pt 4):1081\u20131101","journal-title":"Brain"},{"issue":"2","key":"7963_CR66","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","volume":"234","author":"S Viegas","year":"2012","unstructured":"Viegas S, Jacobson L, Waters P et al (2012) Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 234(2):506\u2013512","journal-title":"Exp Neurol"},{"issue":"7416","key":"7963_CR67","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11348","volume":"489","author":"N Yumoto","year":"2012","unstructured":"Yumoto N, Kim N, Burden S (2012) Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses. Nature 489(7416):438\u2013442","journal-title":"Nature"},{"issue":"2","key":"7963_CR68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","volume":"69","author":"O Higuchi","year":"2011","unstructured":"Higuchi O, Hamuro J, Motomura M et al (2011) Autoantibodies to low-density lipoprotein receptor\u2013related protein 4 in Myasthenia Gravis. Ann Neurol 69(2):418\u2013422","journal-title":"Ann Neurol"},{"issue":"3","key":"7963_CR69","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","volume":"259","author":"A Pevzner","year":"2012","unstructured":"Pevzner A, Schoser B, Peters K et al (2012) Anti-LRP4 autoantibodies in AChR- and MuSK-antibody negative myasthenia gravis. J Neurol 259(3):427\u2013435","journal-title":"J Neurol"},{"issue":"4","key":"7963_CR70","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","volume":"69","author":"B Zhang","year":"2012","unstructured":"Zhang B, Tzartos JS, Belimezi M et al (2012) Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 69(4):445\u2013451","journal-title":"Arch Neurol"},{"key":"7963_CR71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","volume":"52","author":"P Zisimopoulou","year":"2014","unstructured":"Zisimopoulou P, Evangelakou P, Tzartos J et al (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139\u2013145","journal-title":"J Autoimmun"},{"issue":"3","key":"7963_CR72","doi-asserted-by":"crossref","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang B, Shen C, Bealmear B et al (2014) Autoantibodies to agrin in myasthenia gravis patients. PLoS One 9(3):e91816","journal-title":"PLoS One"},{"issue":"22","key":"7963_CR73","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","volume":"82","author":"C Gasperi","year":"2014","unstructured":"Gasperi C, Melms A, Schoser B et al (2014) Anti-agrin autoantibodies in myasthenia gravis. Neurology 82(22):1976\u20131983","journal-title":"Neurology"},{"issue":"4","key":"7963_CR74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1083\/jcb.200307164","volume":"165","author":"A Cartaud","year":"2004","unstructured":"Cartaud A, Strochlic L, Guerra M et al (2004) MuSK is required for anchoring acetylcholinesterase at the neuromuscular junction. J Cell Biol 165(4):505\u2013515","journal-title":"J Cell Biol"},{"issue":"1\u20132","key":"7963_CR75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","volume":"348","author":"M Katarzyna","year":"2015","unstructured":"Katarzyna M, Belaya K, Leite M et al (2015) Collagen Q\u2014a potential target for autoantibodies in myasthenia gravis. J Neurol Sci 348(1\u20132):241\u2013244","journal-title":"J Neurol Sci"},{"issue":"20","key":"7963_CR76","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","volume":"78","author":"MI Leite","year":"2012","unstructured":"Leite MI, Coutinho E, Lana-Peixoto M et al (2012) Myasthenia gravis and neuromyelitis optica spectrum disorder. A multicenter study of 16 patients. Neurology 78(20):1601\u20131607","journal-title":"Neurology"},{"issue":"5","key":"7963_CR77","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1212\/01.wnl.0000234142.41728.a0","volume":"67","author":"M Gotkine","year":"2006","unstructured":"Gotkine M, Fellig Y, Abramsky O (2006) Occurrence of CNS demyelinating disease in patients with myasthenia gravis. Neurology 67(5):881\u2013883","journal-title":"Neurology"},{"issue":"6","key":"7963_CR78","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1191\/1352458503ms964oa","volume":"9","author":"CM Isbister","year":"2003","unstructured":"Isbister CM, Mackenzie PJ, Anderson D (2003) Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler 9(6):550\u2013553","journal-title":"Mult Scler"},{"issue":"3","key":"7963_CR79","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.msard.2013.01.003","volume":"2","author":"J Spillane","year":"2013","unstructured":"Spillane J, Christofi G, Sidle KC et al (2013) Myasthenia gravis and neuromyelitis optica: a causal link. Mult Scler Relat Disord 2(3):233\u2013237","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"7963_CR80","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","volume":"14","author":"CT Bever","year":"1983","unstructured":"Bever CT, Aquino AV, Penn AS et al (1983) Prognosis of ocular myasthenia. Ann Neurol 14(5):516\u2013519","journal-title":"Ann Neurol"},{"key":"7963_CR81","doi-asserted-by":"crossref","unstructured":"Sommer N, Sigg B, Melms A et al (1997) Ocular myasthenia gravis: response to long term immunosuppressive treatment. J Neurol Neurosurg Psychiatry 62(2):156\u2013162","DOI":"10.1136\/jnnp.62.2.156"},{"issue":"8","key":"7963_CR82","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","volume":"256","author":"MJ Kupersmith","year":"2009","unstructured":"Kupersmith MJ (2009) Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up. J Neurol 256(8):1314\u20131320","journal-title":"J Neurol"},{"key":"7963_CR83","doi-asserted-by":"crossref","unstructured":"Wong SH, Plant GT, Cornblath W (2015) Does treatment of ocular myasthenia gravis with early immunosuppressive therapy prevent secondarily generalization and should it be offered to all such patients? J Neuroophthalmol [Epub ahead of print]","DOI":"10.1097\/WNO.0000000000000270"},{"issue":"4","key":"7963_CR84","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","volume":"23","author":"J Mee","year":"2003","unstructured":"Mee J, Paine M, Byrne E et al (2003) Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol 23(4):251\u2013255","journal-title":"J Neuroophthalmol"},{"issue":"2","key":"7963_CR85","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","volume":"37","author":"D Grob","year":"2008","unstructured":"Grob D, Brunner N, Namba T et al (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37(2):141\u2013149","journal-title":"Muscle Nerve"},{"key":"7963_CR86","unstructured":"Wong S, Petrie A, Plant G (2015) Ocular MG: towards a risk of generalisation (\u2018ROG\u2019) score. In: Association of British Neurologists (ABN) annual meeting, final programme and abstract book, 2015 May 20-2; Harrogate, UK: ABN; 2015 p 48"},{"issue":"1","key":"7963_CR87","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11910-010-0151-1","volume":"11","author":"V Kumar","year":"2011","unstructured":"Kumar V, Kaminski HJ (2011) Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 11(1):89\u201396","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"7963_CR88","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B et al (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 50(6):1778\u20131783","journal-title":"Neurology"},{"issue":"11","key":"7963_CR89","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1471-2377-11-97","volume":"5","author":"J Heckmann","year":"2011","unstructured":"Heckmann J, Rawoot A, Bateman K et al (2011) A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 5(11):97","journal-title":"BMC Neurol"},{"issue":"1","key":"7963_CR90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","volume":"30","author":"L Zhou","year":"2004","unstructured":"Zhou L, McConville J, Chaudhry V et al (2004) Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients. Muscle Nerve 30(1):55\u201360","journal-title":"Muscle Nerve"},{"issue":"6","key":"7963_CR91","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","volume":"82","author":"P Maddison","year":"2011","unstructured":"Maddison P, McConville J, Farrugia ME et al (2011) The use of rituximab in myasthenia gravis and Lambert Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 82(6):671\u2013673","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"7963_CR92","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","volume":"78","author":"J D\u00edaz-Manera","year":"2012","unstructured":"D\u00edaz-Manera J, Mart\u00ednez-Hern\u00e1ndez E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78(3):189\u2013193","journal-title":"Neurology"},{"issue":"5","key":"7963_CR93","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00415-014-7532-3","volume":"262","author":"R Iorio","year":"2015","unstructured":"Iorio R, Damato V, Aboini PE et al (2015) Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis. J Neurol 262(5):1115\u20131119","journal-title":"J Neurol"},{"issue":"8","key":"7963_CR94","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00415-013-6987-y","volume":"260","author":"V Catzola","year":"2013","unstructured":"Catzola V, Battaglia A, Buzzonetti A et al (2013) Changes in regulatory T-cells after rituximab in two patients with refractory myasthenia gravis. J Neurol 260(8):2163\u20132165","journal-title":"J Neurol"},{"issue":"1","key":"7963_CR95","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.23839","volume":"48","author":"JF Howard","year":"2013","unstructured":"Howard JF, Barohn RJ, Cutter GR et al (2013) A randomized, double-blind, placebo-controlled phase II trial of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 48(1):76\u201384","journal-title":"Muscle Nerve"},{"key":"7963_CR96","unstructured":"Clinical trials.gov. Safety and efficacy of eculizumab in refractory generalized myasthenia gravis (REGAIN study). ClinicalTrials.gov identifier NCT01997229 [on-line]. Web-page last updated 2015 July 6. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01997229 . Accessed 13 Aug 2015"},{"issue":"7","key":"7963_CR97","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1212\/01.wnl.0000267884.39468.7a","volume":"69","author":"Z Argov","year":"2007","unstructured":"Argov Z, McKee D, Agus S et al (2007) Treatment of human myasthenia with oral antisense suppression of acetylcholinesterase. Neurology 69(7):699\u2013700","journal-title":"Neurology"},{"key":"7963_CR98","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1749-6632.2012.06825.x","volume":"1275","author":"J Sussman","year":"2012","unstructured":"Sussman J, Argov Z, Wirguin Y et al (2012) Further developments with antisense treatment for myasthenia gravis. Ann N Y Acad Sci 1275:13\u201316","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"7963_CR99","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s13311-015-0345-y","volume":"12","author":"DB Sanders","year":"2015","unstructured":"Sanders DB, Rosenfeld J, Dimachkie MM et al (2015) A double-blinded, randomized, placebo-controlled trial to evaluate efficacy, safety, and tolerability of single doses of Tirasemtiv in patients with acetylcholine receptor-binding antibody-positive myasthenia gravis. Neurotherapeutics 12(2):455\u2013460","journal-title":"Neurotherapeutics"},{"issue":"23","key":"7963_CR100","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nouri MN, Ng E et al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23):2017\u20132023","journal-title":"Neurology"},{"key":"7963_CR101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06767.x","volume":"1275","author":"V Bril","year":"2012","unstructured":"Bril V, Barnett-Tapia C, Barth D et al (2012) IVIg and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci 1275:1\u20136","journal-title":"Ann N Y Acad Sci"},{"key":"7963_CR102","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1749-6632.2012.06799.x","volume":"1275","author":"A Marx","year":"2012","unstructured":"Marx A, Pfister F, Schalke B et al (2012) Thymus pathology observed in the MGTX trial. Ann N Y Acad Sci 1275:92\u2013100","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"7963_CR103","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","volume":"64","author":"L Lauriola","year":"2005","unstructured":"Lauriola L, Ranelletti F, Maggiano N et al (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 64(3):536\u2013538","journal-title":"Neurology"},{"issue":"3","key":"7963_CR104","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","volume":"57","author":"MI Leite","year":"2005","unstructured":"Leite MI, Str\u00f6bel P, Jones M et al (2005) Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 57(3):444\u2013448","journal-title":"Ann Neurol"},{"key":"7963_CR105","doi-asserted-by":"crossref","unstructured":"Saka E, Topcuoglu MA, Akkaya B et al (2005) Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 65(5):782\u2013783 (author reply 782\u20133)","DOI":"10.1212\/WNL.65.5.782"},{"issue":"6","key":"7963_CR106","doi-asserted-by":"crossref","first-page":"S2128","DOI":"10.1016\/j.athoracsur.2010.02.099","volume":"89","author":"JB Shrager","year":"2010","unstructured":"Shrager JB (2010) Extended transcervical thymectomy: the ultimate minimally invasive approach. Ann Thorac Surg 89(6):S2128\u2013S2134","journal-title":"Ann Thorac Surg"},{"key":"7963_CR107","doi-asserted-by":"crossref","unstructured":"Freeman RK, Ascioti AJ, van Woerkom JM et al (2011) Long-term follow-up after robotic thymectomy for nonthymomatous myasthenia gravis. Ann Thorac Surg 92(3):1018\u20131022 (discussion 1022\u20133)","DOI":"10.1016\/j.athoracsur.2011.04.054"},{"key":"7963_CR108","doi-asserted-by":"crossref","unstructured":"Marulli G, Schiavon M, Perissinotto E et al (2013) Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. J Thorac Cardiovasc Surg 145(3):730\u2013735 (discussion 735\u20136)","DOI":"10.1016\/j.jtcvs.2012.12.031"},{"issue":"7","key":"7963_CR109","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1007\/s00415-013-6880-8","volume":"260","author":"J Spillane","year":"2013","unstructured":"Spillane J, Hayward M, Hirsch NP et al (2013) Thymectomy: role in the treatment of myasthenia gravis. J Neurol 260(7):1798\u20131801","journal-title":"J Neurol"},{"issue":"1","key":"7963_CR110","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/ejcts\/ezu352","volume":"48","author":"M Keijzers","year":"2015","unstructured":"Keijzers M, de Baets M, Hochstenbag M et al (2015) Robotic thymectomy in patients with myasthenia gravis: neurological and surgical outcomes. Eur J Cardiothorac Surg 48(1):40\u201345","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"7963_CR111","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jtcvs.2010.11.042","volume":"141","author":"JC R\u00fcckert","year":"2011","unstructured":"R\u00fcckert JC, Swierzy M, Ismail M (2011) Comparison of robotic and nonrobotic thoracoscopic thymectomy: a cohort study. J Thorac Cardiovasc Surg 141(3):673\u2013677","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7963-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-015-7963-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-015-7963-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,2]],"date-time":"2019-09-02T23:02:06Z","timestamp":1567465326000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-015-7963-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,24]]},"references-count":111,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["7963"],"URL":"https:\/\/doi.org\/10.1007\/s00415-015-7963-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,24]]}}}